PURPOSE: The Charlson comorbidity index (CCI) is a commonly used scale for assessing morbidity, but its role in assessing mortality in hemodialysis patients is not clear. Age, a component of CCI, is a strong risk factor for morbidity and mortality in chronic diseases and correlates with comorbidities. We hypothesized that the Charlson comorbidity index without age is a strong predictor of mortality in hemodialysis patients. METHODS: A 6-year cohort of 893 hemodialysis patients was examined for an association between a modified CCI (without age and kidney disease) (mCCI) and mortality. RESULTS: Patients were 53±15 years old (mean±SD), had a median mCCI score of 2, and included 47% women, 31% African Americans and 55% diabetics. After adjusting for case-mix and nutritional and inflammatory markers including C-reactive protein and interleukin-6, 2nd (mCCI: 1-2), 3rd (mCCI=3), and 4th (mCCI: 4-9) quartiles compared to 1st (mCCI=0) quartiles showed death hazard ratios (95% confidence intervals) of 1.43 (0.92-2.23), 1.70 (1.06-2.72), and 2.33 (1.43-3.78), respectively. The mCCI-death association was robust in non-African Americans. The CCI-death association linearity was verified in cubic splines. Each 1 unit higher mCCI score was associated with a death hazard ratio of 1.16 (1.07-1.27). CONCLUSIONS: CCI independent of age is a robust and linear predictor of mortality in hemodialysis patients, in particular in non-African Americans.
Charlson comorbidity score is a strong predictor of mortality in hemodialysis patients.
Charlson合并症评分是血液透析患者死亡率的强预测因子
阅读:10
作者:Rattanasompattikul Manoch, Feroze Usama, Molnar Miklos Z, Dukkipati Ramanath, Kovesdy Csaba P, Nissenson Allen R, Norris Keith C, Kopple Joel D, Kalantar-Zadeh Kamyar
| 期刊: | International Urology and Nephrology | 影响因子: | 1.900 |
| 时间: | 2012 | 起止号: | 2012 Dec;44(6):1813-23 |
| doi: | 10.1007/s11255-011-0085-9 | 研究方向: | 其它 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
